Selinexor + Bispecific Antibody
A Phase II Safety and Efficacy Study of Selinexor in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 27 patients (estimated)
- Sponsors
- Duke Cancer Center
- Tags
- Bispecific T Cell Engager (BiTE), Bispecific Antibody, CD3, B-Cell Maturation Antigen (BCMA), GPRC5D
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2167
- NCT Identifier
- NCT06822972
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.